LinkedIn Profile

Access Castle Biosciences historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:castlebiosciences 2275154 May 28th, 2020 12:00AM Castle Biosciences, Inc. 3.1K 128.00 Open Biotechnology May 28th, 2020 02:11PM May 28th, 2020 02:11PM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 27th, 2020 12:00AM Castle Biosciences, Inc. 3.0K 128.00 Open Biotechnology May 27th, 2020 12:08AM May 27th, 2020 12:08AM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 26th, 2020 12:00AM Castle Biosciences, Inc. 3.0K 128.00 Open Biotechnology May 26th, 2020 10:29AM May 26th, 2020 10:29AM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 25th, 2020 12:00AM Castle Biosciences, Inc. 3.0K 128.00 Open Biotechnology May 25th, 2020 12:13AM May 25th, 2020 12:13AM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 24th, 2020 12:00AM Castle Biosciences, Inc. 3.0K 128.00 Open Biotechnology May 24th, 2020 12:07AM May 24th, 2020 12:07AM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 23rd, 2020 12:00AM Castle Biosciences, Inc. 3.0K 128.00 Open Biotechnology May 23rd, 2020 02:57PM May 23rd, 2020 02:57PM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 22nd, 2020 12:00AM Castle Biosciences, Inc. 3.0K 127.00 Open Biotechnology May 22nd, 2020 12:08AM May 22nd, 2020 12:08AM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 21st, 2020 12:00AM Castle Biosciences, Inc. 3.0K 127.00 Open Biotechnology May 21st, 2020 12:58PM May 21st, 2020 12:58PM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 20th, 2020 12:00AM Castle Biosciences, Inc. 3.0K 127.00 Open Biotechnology May 20th, 2020 02:37PM May 20th, 2020 02:37PM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology
private:castlebiosciences 2275154 May 19th, 2020 12:00AM Castle Biosciences, Inc. 3.0K 127.00 Open Biotechnology May 19th, 2020 02:51PM May 19th, 2020 02:51PM Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com. Open Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma Open 820 S Friendswood Dr Friendswood TX US 77546 Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.